Cargando…
African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker
BACKGROUND: Today, the development of new and well-tolerated anti-malarial drugs is strongly justified by the emergence of Plasmodium falciparum resistance. In 2014–2015, a phase 2b clinical study was conducted to evaluate the efficacy of a single oral dose of Artefenomel (OZ439)–piperaquine (PPQ) i...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457011/ https://www.ncbi.nlm.nih.gov/pubmed/30967148 http://dx.doi.org/10.1186/s12936-019-2756-4 |
_version_ | 1783409843929874432 |
---|---|
author | Leroy, Didier Macintyre, Fiona Adoke, Yeka Ouoba, Serge Barry, Aissata Mombo-Ngoma, Ghyslain Ndong Ngomo, Jacques Mari Varo, Rosauro Dossou, Yannelle Tshefu, Antoinette Kitoto Duong, Tran Thanh Phuc, Bui Quang Laurijssens, Bart Klopper, Roland Khim, Nimol Legrand, Eric Ménard, Didier |
author_facet | Leroy, Didier Macintyre, Fiona Adoke, Yeka Ouoba, Serge Barry, Aissata Mombo-Ngoma, Ghyslain Ndong Ngomo, Jacques Mari Varo, Rosauro Dossou, Yannelle Tshefu, Antoinette Kitoto Duong, Tran Thanh Phuc, Bui Quang Laurijssens, Bart Klopper, Roland Khim, Nimol Legrand, Eric Ménard, Didier |
author_sort | Leroy, Didier |
collection | PubMed |
description | BACKGROUND: Today, the development of new and well-tolerated anti-malarial drugs is strongly justified by the emergence of Plasmodium falciparum resistance. In 2014–2015, a phase 2b clinical study was conducted to evaluate the efficacy of a single oral dose of Artefenomel (OZ439)–piperaquine (PPQ) in Asian and African patients presenting with uncomplicated falciparum malaria. METHODS: Blood samples collected before treatment offered the opportunity to investigate the proportion of multidrug resistant parasite genotypes, including P. falciparum kelch13 mutations and copy number variation of both P. falciparum plasmepsin 2 (Pfpm2) and P. falciparum multidrug resistance 1 (Pfmdr1) genes. RESULTS: Validated kelch13 resistance mutations including C580Y, I543T, P553L and V568G were only detected in parasites from Vietnamese patients. In Africa, isolates with multiple copies of the Pfmdr1 gene were shown to be more frequent than previously reported (21.1%, range from 12.4% in Burkina Faso to 27.4% in Uganda). More strikingly, high proportions of isolates with multiple copies of the Pfpm2 gene, associated with piperaquine (PPQ) resistance, were frequently observed in the African sites, especially in Burkina Faso and Uganda (> 30%). CONCLUSIONS: These findings were considered to sharply contrast with the recent description of increased sensitivity to PPQ of Ugandan parasite isolates. This emphasizes the necessity to investigate in vitro susceptibility profiles to PPQ of African isolates with multiple copies of the Pfpm2 gene and estimate the risk of development of PPQ resistance in Africa. Trial registration Clinicaltrials.gov reference: NCT02083380. Study title: Phase II efficacy study of artefenomel and piperaquine in adults and children with P. falciparum malaria. https://clinicaltrials.gov/ct2/results?cond=&term=NCT02083380&cntry=&state=&city=&dist=. FSFV: 23-Jul-2014; LSLV: 09-Oct-2015 |
format | Online Article Text |
id | pubmed-6457011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-64570112019-04-19 African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker Leroy, Didier Macintyre, Fiona Adoke, Yeka Ouoba, Serge Barry, Aissata Mombo-Ngoma, Ghyslain Ndong Ngomo, Jacques Mari Varo, Rosauro Dossou, Yannelle Tshefu, Antoinette Kitoto Duong, Tran Thanh Phuc, Bui Quang Laurijssens, Bart Klopper, Roland Khim, Nimol Legrand, Eric Ménard, Didier Malar J Research BACKGROUND: Today, the development of new and well-tolerated anti-malarial drugs is strongly justified by the emergence of Plasmodium falciparum resistance. In 2014–2015, a phase 2b clinical study was conducted to evaluate the efficacy of a single oral dose of Artefenomel (OZ439)–piperaquine (PPQ) in Asian and African patients presenting with uncomplicated falciparum malaria. METHODS: Blood samples collected before treatment offered the opportunity to investigate the proportion of multidrug resistant parasite genotypes, including P. falciparum kelch13 mutations and copy number variation of both P. falciparum plasmepsin 2 (Pfpm2) and P. falciparum multidrug resistance 1 (Pfmdr1) genes. RESULTS: Validated kelch13 resistance mutations including C580Y, I543T, P553L and V568G were only detected in parasites from Vietnamese patients. In Africa, isolates with multiple copies of the Pfmdr1 gene were shown to be more frequent than previously reported (21.1%, range from 12.4% in Burkina Faso to 27.4% in Uganda). More strikingly, high proportions of isolates with multiple copies of the Pfpm2 gene, associated with piperaquine (PPQ) resistance, were frequently observed in the African sites, especially in Burkina Faso and Uganda (> 30%). CONCLUSIONS: These findings were considered to sharply contrast with the recent description of increased sensitivity to PPQ of Ugandan parasite isolates. This emphasizes the necessity to investigate in vitro susceptibility profiles to PPQ of African isolates with multiple copies of the Pfpm2 gene and estimate the risk of development of PPQ resistance in Africa. Trial registration Clinicaltrials.gov reference: NCT02083380. Study title: Phase II efficacy study of artefenomel and piperaquine in adults and children with P. falciparum malaria. https://clinicaltrials.gov/ct2/results?cond=&term=NCT02083380&cntry=&state=&city=&dist=. FSFV: 23-Jul-2014; LSLV: 09-Oct-2015 BioMed Central 2019-04-10 /pmc/articles/PMC6457011/ /pubmed/30967148 http://dx.doi.org/10.1186/s12936-019-2756-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Leroy, Didier Macintyre, Fiona Adoke, Yeka Ouoba, Serge Barry, Aissata Mombo-Ngoma, Ghyslain Ndong Ngomo, Jacques Mari Varo, Rosauro Dossou, Yannelle Tshefu, Antoinette Kitoto Duong, Tran Thanh Phuc, Bui Quang Laurijssens, Bart Klopper, Roland Khim, Nimol Legrand, Eric Ménard, Didier African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker |
title | African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker |
title_full | African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker |
title_fullStr | African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker |
title_full_unstemmed | African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker |
title_short | African isolates show a high proportion of multiple copies of the Plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker |
title_sort | african isolates show a high proportion of multiple copies of the plasmodium falciparum plasmepsin-2 gene, a piperaquine resistance marker |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457011/ https://www.ncbi.nlm.nih.gov/pubmed/30967148 http://dx.doi.org/10.1186/s12936-019-2756-4 |
work_keys_str_mv | AT leroydidier africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT macintyrefiona africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT adokeyeka africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT ouobaserge africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT barryaissata africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT mombongomaghyslain africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT ndongngomojacquesmari africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT varorosauro africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT dossouyannelle africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT tshefuantoinettekitoto africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT duongtranthanh africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT phucbuiquang africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT laurijssensbart africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT klopperroland africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT khimnimol africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT legranderic africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker AT menarddidier africanisolatesshowahighproportionofmultiplecopiesoftheplasmodiumfalciparumplasmepsin2geneapiperaquineresistancemarker |